Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 3 Interventional

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

NCT06151197
View directory record Official record
Conditions
Plantar Fibromatosis, Ledderhose Disease
Interventions
EN3835, Placebo
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
63
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 7:21 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

NCT00510874
View directory record Official record
Conditions
Influenza
Interventions
Pumarix™, Pandemrix ™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 24, 2026, 7:21 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597
View directory record Official record
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 24, 2026, 7:21 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 1 Interventional

Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment

NCT00105417
View directory record Official record
Conditions
HIV Infections, HIV
Interventions
IL-7
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity

NCT01313299
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

NCT00829595
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

NCT02683928
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GBR 830, Placebo
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

NCT01742221
View directory record Official record
Conditions
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions
HemaMax, Placebo
Biological · Drug
Lead sponsor
Neumedicines Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Not applicable Interventional Results available

The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension

NCT00979732
View directory record Official record
Conditions
Hypertension
Interventions
grape seed extract, grape seed extract placebo
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
25 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

NCT01873404
View directory record Official record
Conditions
Painful Lumbar Radiculopathy, Sciatica, Radiculopathy
Interventions
BG00010, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • Fresno, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Results available

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507
View directory record Official record
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence in Diabetes

NCT03983499
View directory record Official record
Conditions
Type 2 Diabetes, Glycemic Control, Cardiovascular Risk Factors, Psychological Distress
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 3 Interventional

Intermittent vs. Continuous HAART to Treat Chronic HIV Infection

NCT00025909
View directory record Official record
Conditions
HIV Infection
Interventions
Leukapheresis
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

NCT03317899
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Plasma Cell Myeloma
Interventions
Hematopoietic Cell Transplantation, Tbo-filgrastim, Laboratory Biomarker Analysis
Procedure · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 24, 2026, 7:21 AM EDT
Enrolling by invitation No phase listed Observational

Comparison of Human Allograft to Apligraf for Venous Leg Ulcers

NCT02047084
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Not listed
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
21 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 7:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears

NCT05997381
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Arthroscopic rotator cuff repair with BioBrace® Implant augmentation., Arthroscopic rotator cuff repair
Device · Procedure
Lead sponsor
CONMED Corporation
Industry
Eligibility
40 Years to 70 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 7:21 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

NCT04368728
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b1, BNT162b2, Placebo, BNT162b2SA
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
46,969 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
154
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 24, 2026, 7:21 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia

NCT07615075
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Healthy
Interventions
Placebo, IL-23
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 7:21 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

NCT00035581
View directory record Official record
Conditions
HIV Seropositivity, HIV Infection
Interventions
poly I-poly C12U
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
7
States / cities
Fountain Valley, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 24, 2026, 7:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers

NCT05698212
View directory record Official record
Conditions
Endometriosis, Diagnosis
Interventions
MetriDx
Diagnostic Test
Lead sponsor
Hera Biotech, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Saginaw, Michigan • Corpus Christi, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 24, 2026, 7:21 AM EDT